Literature DB >> 1335647

Simultaneous vaccination against hepatitis A and B: results of a controlled study.

F Ambrosch1, F E André, A Delem, E D'Hondt, S Jonas, C Kunz, A Safary, G Wiedermann.   

Abstract

Hepatitis A and hepatitis B are endemic in many countries and must be considered as serious health risks for large parts of the world population. Simultaneous or combined vaccination against these two diseases would therefore be most advantageous. In order to investigate possible interactions between these vaccines with respect to their tolerability and immunogenicity, we conducted a randomized prospective study comparing single and simultaneous administration of the two vaccines. Three groups of healthy volunteers, each with 55 persons, were included in the study. All were negative for hepatitis A and hepatitis B markers and had normal serum liver enzyme values. Group I received hepatitis A vaccine (720 ELISA units) into the left deltoid muscle, group II received hepatitis B vaccine (20 micrograms) into the right deltoid muscle and group III received hepatitis A vaccine into the left, and hepatitis B vaccine into the right deltoid muscle. Three doses of the vaccines were administered at 0, 1 and 6 months. Local and systemic reactions were monitored by means of questionnaires. Blood samples for determination of antibody to hepatitis A virus (anti-HAV) and antibody to hepatitis B surface antigen (anti-HBs) and of serum SGOT and SGPT levels were drawn at months 0, 1, 2, 6 and 7. There were no serious general and only mild local reactions. The mean serum SGOT and SGPT values remained in the normal range in all groups. The seroconversion rates and mean geometric titres of the anti-HAV and anti-HBs antibodies were similar when the vaccines were administered separately or simultaneously. There were no significant differences between the compared groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335647     DOI: 10.1016/0264-410x(92)90570-a

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Preventing hepatitis A infections. National Advisory Committee on Immunization statement. Laboratory Centre for Disease Control.

Authors: 
Journal:  Can Fam Physician       Date:  1995-07       Impact factor: 3.275

2.  Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth.

Authors:  N Linder; R Handsher; B German; L Sirota; M Bachman; S Zinger; E Mendelson; A Barzilai
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-07       Impact factor: 5.747

Review 3.  Infectious diseases.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  1994-02       Impact factor: 2.401

Review 4.  New developments in hepatitis A control.

Authors:  L Yuan
Journal:  Can Fam Physician       Date:  1995-07       Impact factor: 3.275

Review 5.  Safety and effectiveness of the new inactivated hepatitis A virus vaccine.

Authors:  J Furesz; D W Scheifele; L Palkonyay
Journal:  CMAJ       Date:  1995-02-01       Impact factor: 8.262

6.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

7.  Statistical and Ontological Analysis of Adverse Events Associated with Monovalent and Combination Vaccines against Hepatitis A and B Diseases.

Authors:  Jiangan Xie; Lili Zhao; Shangbo Zhou; Yongqun He
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.